Research blend

CJC-1295 / Ipamorelin / Sermorelin blend

CJC-1295 / Ipamorelin / Sermorelin

Specification

Total quantity: 30 mg
Pack: Sealed glass vial(s); vial count confirmed before release
Form: Lyophilised powder
Stated purity: Reported per lot on the certificate of analysis
Appearance: White to off-white lyophilised powder in a sealed glass vial under an aluminium crimp seal.
Storage: 2–8 °C, sealed, protected from light
Shipping: Dispatched from the United Kingdom Monday to Wednesday only, under cold chain in insulated packaging with coolant, so that no consignment is held over a weekend in transit.
SKU: HX-CIS-30

AvailabilityOut of stock

Pricing releasing soon. Leave an email to be told once, or request a wholesale quote now.

Request a wholesale quote

For laboratory research use only. Not for human or veterinary consumption.

Analytical data

Latest released lotNo released lot yet

Analytical data appear here as soon as the first lot is released. Every released lot carries a certificate with HPLC purity and MS identity per compound.

Method

Purity by reversed-phase HPLC with UV detection; identity by electrospray mass spectrometry against the calculated monoisotopic or average mass. Endotoxin where stated. The certificate names the laboratory and the method for every result.

How to read a certificate →

Identity

Identity · CJC-1295verified 2026-09-21

Synonyms: —
CAS: Not yet verified
UNII: Not yet verified
PubChem CID: Not yet verified
Formula: Not yet verified
Mol. weight: Not yet verified
Class: Not yet verified
Targets: None identified in retrieved sources

Identity · Ipamorelinverified 2026-09-21

Synonyms: NNC 26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2, 2-Methylalanyl-L-histidyl-3-(2-naphthalenyl)-D-alanyl-D-phenylalanyl-L-lysinamide, Ipamorelina, Ipamoreline
CAS: 170851-70-4· PubChem, National Center for Biotechnology Information, FDA / NCATS Global Substance Registration System, US Food and Drug Administration
UNII: Y9M3S784Z6· FDA / NCATS Global Substance Registration System, PubChem, National Center for Biotechnology Information, US Food and Drug Administration
PubChem CID: 9831659
Formula: C₃₈H₄₉N₉O₅· PubChem, National Center for Biotechnology Information, FDA / NCATS Global Substance Registration System, European Bioinformatics Institute, US Food and Drug Administration
Mol. weight: 711.9 g/mol· PubChem, National Center for Biotechnology Information, FDA / NCATS Global Substance Registration System, European Bioinformatics Institute, US Food and Drug Administration
Class: Synthetic pentapeptide growth hormone secretagogue (ghrelin mimetic)
Targets: Growth hormone secretagogue receptor type 1a (GHSR-1a, ghrelin receptor) - agonist
Modifications: N-terminal 2-aminoisobutyric acid (Aib); D-2-naphthylalanine at position 3 and D-phenylalanine at position 4; C-terminal lysinamide (amidated C-terminus). No disulfide bridge, glycosylation or lipidation is described in the sources retrieved.

Sequence · 9 residues

Identity · Sermorelinverified 2026-09-21

Synonyms: GRF(1-29)NH2, GHRH(1-29)NH2, hGHRH(1-29)NH2, Growth hormone-releasing factor (human)-(1-29)-peptide amide, Somatotropin-releasing-hormone(1-29)amide, Groliberin, Sermorelinum, Sermoreline, Sermorelina, Sermorelin acetate (USAN), Geref (brand)
CAS: 86168-78-7· PubChem, NCBI/NLM, FDA / NCATS GSRS
UNII: 89243S03TE· PubChem, NCBI/NLM, FDA / NCATS GSRS
PubChem CID: 16132413
Formula: C₁₄₉H₂₄₆N₄₄O₄₂S· PubChem, NCBI/NLM
Mol. weight: 3357.9 g/mol· PubChem, NCBI/NLM, FDA / NCATS GSRS, Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS
Class: Synthetic linear 29-residue peptide amide; N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH, somatoliberin); GHRH receptor agonist. ATC H01AC04 and V04CD03.
Targets: Growth hormone-releasing hormone receptor (GHRHR; ChEMBL target CHEMBL2032), agonist
Modifications: C-terminal amidation: residue 29 is L-argininamide (GSRS records an amino-acid substitution ARGININE -> ARGININAMIDE, L- at position 29). Free N-terminus (H-Tyr1). Sequence is identical to residues 1-29 of mature human somatoliberin (UniProt P01286 residues 32-60); no non-natural residues. No disulfide bonds (no Cys).

Sequence (one-letter) · 29 residues

Identity fields marked “not yet verified” are withheld until they can be traced to a retrieved primary source. Nothing is shown from memory or from supplier catalogues.

Research overview

The preparation contains three compounds. CJC-1295 is a name applied to two chemically distinct analogues of growth hormone-releasing hormone fragment 1-29: the 30-residue form carrying an albumin-binding drug affinity complex, CAS 446262-90-4, UNII 62RC32V9N7, C165H269N47O46, 3647.2 g/mol, and the 29-residue tetrasubstituted form without it, CAS 446036-97-1, C152H252N44O42, 3367.9 g/mol, which has no UNII; FDA regards each as a different active moiety ¹²³. Ipamorelin is a synthetic pentapeptide growth hormone secretagogue acting at the growth hormone secretagogue receptor type 1a, recorded as CAS 170851-70-4, UNII Y9M3S784Z6, C38H49N9O5, 711.9 g/mol ⁴⁵⁶. Sermorelin is the synthetic 29-residue amide corresponding to the N-terminal fragment of human growth hormone-releasing hormone, sequence YADAIFTNSYRKVLGQLSARKLLQDIMSR, CAS 86168-78-7, UNII 89243S03TE, C149H246N44O42S, 3357.9 g/mol; sermorelin acetate was the active substance of a product approved in the United States in 1990 and now listed as discontinued ⁷⁸⁹. All three are named in section S2.2.4 of the World Anti-Doping Agency Prohibited List in force ¹⁰. The linked monographs set out identifiers, the published literature and dated status for each compound separately.

1.GSRS substance record CJC-1295, UNII 62RC32V9N7 (full view, retrieved through the GSRS API). FDA Global Substance Registration System, NCATS (2026). source
2.PubChem CID 56841945, 29-residue tetrasubstituted GRF(1-29) amide (retrieved through PUG REST identity search, properties and synonyms). PubChem, National Center for Biotechnology Information (2026). source
3.Mai Tu, Edna Albuquerque, Andrea Benedict, Marianne San Antonio, Suhail Kasim, Ashlee Mattingly, Tracy Rupp. FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: Evaluation of five CJC-1295-related bulk drug substances. U.S. Food and Drug Administration (2024). source
4.Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998). doi:10.1530/eje.0.1390552
5.Ipamorelin, CID 9831659 - properties, synonyms and structure. PubChem, National Center for Biotechnology Information (2026). source
6.IPAMORELIN substance record (UNII Y9M3S784Z6), Global Substance Registration System. FDA / NCATS Global Substance Registration System (2026). source
7.SERMORELIN (UNII 89243S03TE) - Global Substance Registration System. FDA / NCATS GSRS (2026). source
8.Sermorelin (CID 16132413). PubChem, NCBI/NLM (2026). source
9.Drugs@FDA: GEREF (sermorelin acetate), NDA 019863. US Food and Drug Administration (2026). source
10.The Prohibited List (List of Prohibited Substances and Methods in force). World Anti-Doping Agency (2026). source

CJC-1295 monograph Ipamorelin monograph Sermorelin monograph

Regulatory status

Regulatory status · CJC-1295Investigational or unlicensed compound

No medicine containing this compound is authorised in any jurisdiction checked. It has no established safety profile in humans outside registered clinical research. It is supplied for laboratory research only.

The rows below record the absence of authorisation and any compounding, evaluation or anti-doping status found on the date checked.

United Kingdom: No marketing authorisation: no CJC-1295 entry was found in the MHRA products substance index on 21 September 2026, and FDA records that no approved product containing any form of CJC-1295 exists in the United Kingdom.Checked 2026-09-21 · Medicines and Healthcare products Regulatory Agency
European Union: No authorisation: the Union Register of medicinal products contains no CJC-1295 entry, and FDA records that no product containing any form of CJC-1295 has been authorised in the European Union.Checked 2026-09-21 · European Commission
United States: No form of CJC-1295 is an approved drug or a component of an approved drug; it is not on the 503A bulks list, and FDA lists it among bulk drug substances that may present significant safety risks.Checked 2026-09-21 · Office of the Federal Register (eCFR)
WADA Prohibited List: Prohibited at all times under section S2.2.4 of the 2026 Prohibited List, where CJC-1295 is named as an example of a GHRH analogue; all substances in class S2 are non-specified substances.Checked 2026-09-21 · World Anti-Doping Agency

Regulatory status · IpamorelinInvestigational or unlicensed compound

The rows below record the absence of authorisation and any compounding, evaluation or anti-doping status found on the date checked.

United Kingdom: No record of any ipamorelin medicine was found in the MHRA products register or the eMC on 2026-09-21.Checked 2026-09-21 · Medicines and Healthcare products Regulatory Agency
European Union: No entry for ipamorelin was found in the EU Union Register of medicinal products for human use on 2026-09-21.Checked 2026-09-21 · European Commission, DG Health and Food Safety
United States: Ipamorelin is not an approved drug substance; ipamorelin acetate sits in category 2 of the FDA 503B interim policy for significant safety risks, and in October 2024 the Pharmacy Compounding Advisory Committee voted against adding either form to the 503A Bulks List.Checked 2026-09-21 · US Food and Drug Administration
WADA Prohibited List: Ipamorelin is named in the Prohibited List in force under S2.2.4, growth hormone releasing factors, and is prohibited at all times.Checked 2026-09-21 · World Anti-Doping Agency

Regulatory status · SermorelinInvestigational or unlicensed compound

The rows below record the absence of authorisation and any compounding, evaluation or anti-doping status found on the date checked.

United Kingdom: No sermorelin product was found in the MHRA products register or the eMC on 2026-09-21; sermorelin was added to the UK prescription-only substances schedule by SI 1993/1890.Checked 2026-09-21 · Medicines and Healthcare products Regulatory Agency
European Union: No centrally authorised, withdrawn or refused medicine containing sermorelin appears in the EMA medicines dataset generated on 2026-09-21; national authorisations were not verified.Checked 2026-09-21 · European Medicines Agency
United States: Formerly FDA-approved as Geref (sermorelin acetate; EMD Serono) under NDA 019863 (1990) and NDA 020443 (1997); both are listed as Discontinued, and FDA determined in 2013 that they were not withdrawn for reasons of safety or effectiveness.Checked 2026-09-21 · US Food and Drug Administration
WADA Prohibited List: Sermorelin is named in section S2.2.4 (growth hormone releasing factors) of the Prohibited List shown as the latest version on wada-ama.org on 2026-09-21 (2026 List); S2 is prohibited at all times.Checked 2026-09-21 · World Anti-Doping Agency

Handling and safety

Handle as a research chemical of unknown hazard in a laboratory setting with appropriate protective equipment. Keep sealed at 2–8 °C and protected from light. Safety data sheet: available on request until the SDS is published here.

Shipping

Dispatched in insulated cold-chain packaging with a coolant, Monday to Wednesday, to laboratory and business addresses within the United Kingdom. Destination rules are on the shipping policy.

Questions

Which identity records do the three components correspond to?: Ipamorelin: CAS 170851-70-4, UNII Y9M3S784Z6, PubChem CID 9831659 [gsrs-ipamorelin-2026][pubchem-cid-9831659]. Sermorelin: CAS 86168-78-7, UNII 89243S03TE, PubChem CID 16132413 [gsrs-89243s03te][pubchem-16132413]. For CJC-1295 the molecule is not yet confirmed: the form with the drug affinity complex and the form without it have different CAS numbers, formulas and molecular weights, and only the first has a UNII [fda-pcac-cjc1295-2024].
How does one certificate of analysis cover three compounds?: Each compound carries its own lines on the same certificate: a chromatographic purity figure with the high-performance liquid chromatography method used, and a mass-spectrometric identity line giving the method, the expected and observed masses and whether identity was confirmed, together with assayed mass and net peptide content. Three components therefore produce three result rows on one certificate, and no combined purity figure is recorded.
Can intact-mass measurement distinguish the three components?: The published molecular weights differ: about 711.9 g/mol for ipamorelin, about 3357.9 for sermorelin, and about 3367.9 or 3647.2 for the two CJC-1295 forms [pubchem-cid-9831659][pubchem-16132413][pubchem-cid56841945][gsrs-62rc32v9n7]. Sermorelin and the CJC-1295 form without the drug affinity complex differ by about 10 g/mol, which is why identity is recorded per compound against a stated expected mass rather than for the preparation as a whole.
Is a compendial specification available for the components?: No pharmacopoeial monograph, official reference standard or impurity specification exists for any CJC-1295-related substance, so no compendial specification can be quoted for that line and each certificate line rests on the stated method [fda-pcac-cjc1295-2024].
Why are the solubility and solution-stability fields empty?: Because no source on this site's allow-list characterises the three-component mixture. Figures published for the individual compounds are set out in the linked monographs, where they are attributed to the evaluation that reproduced them. Nothing is entered here that could not be traced to a retrieved source for this material.
What does the pack contain?: Lyophilised powder in a sealed glass vial holding 30 mg of peptide in total across the three components, held at 2 to 8 °C and protected from light until dispatch. The mass of each component has not been confirmed, so the specification panel states total quantity only. Vials are sealed at fill and are not opened again before shipping.